Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03596567 · ClinicalTrials.gov registry record · Phase 1
Glasdegib Renal Impairment Study
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03596567 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 18 participants.
The verdict
NCT03596567, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The goal of this study is to administer single dose (100 mg) glasdegib tablet to subjects with normal, moderate and severe renal impairment and estimate the effect, if any, of this renal impairment on glasdegib pharmacokinetics.
Interventions
- DRUG Glasdegib single 100 mg dose in normal healthy subjects
- DRUG Glasdegib single 100 mg dose in moderate renal impairment subjects
- DRUG Glasdegib single 100 mg dose in severe renal impairment subjects
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-05-17 |
| Est. Completion | 2018-09-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03596567
The ClinicalTrials.gov registry entry for NCT03596567 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Glasdegib single 100 mg dose in normal healthy subjects is the first listed.
NCT03596567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03596567 about?
NCT03596567 is a clinical study titled "Glasdegib Renal Impairment Study". The goal of this study is to administer single dose (100 mg) glasdegib tablet to subjects with normal, moderate and severe renal impairment and estimate the effect, if any, of this renal impairment on glasdegib pharmacokinetics.
What is the current status of trial NCT03596567?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2018-05-17. Estimated completion is 2018-09-19.
What interventions are being tested in trial NCT03596567?
The interventions under investigation include: Glasdegib single 100 mg dose in normal healthy subjects (DRUG), Glasdegib single 100 mg dose in moderate renal impairment subjects (DRUG), Glasdegib single 100 mg dose in severe renal impairment subjects (DRUG).
Who is sponsoring clinical trial NCT03596567?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.